Compare Kymera Therapeutics Inc. Common Stock (KYMR) vs Quantumscape Corp (QS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kymera Therapeutics Inc. Common Stock vs Quantumscape Corp — how do they compare? Kymera Therapeutics Inc. Common Stock trades at $106.9 (market cap $8.87B), while Quantumscape Corp trades at $3.91 (market cap $2.55B). The key difference: Kymera Therapeutics Inc. Common Stock is far larger — about 3.5× Quantumscape Corp's market cap, and Kymera Therapeutics Inc. Common Stock is trading nearer its 52-week high, Quantumscape Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Kymera Therapeutics Inc. Common Stock for 0 Days and Quantumscape Corp for 37 Days on average.
| KYMR | QS | |
|---|---|---|
Market Cap | $8.87B | $2.55B |
Volume | 779,107 | 12,145,789 |
Sector | Health | Consumer Cyclical |
52-Week High | $127.31 | $18.44 |
52-Week Low | $55.80 | $3.93 |
Typical Hold Time | 0 Days | 37 Days |
Enterprise Value | $8.26B | $1.76B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
QuantumScape (QS) trades at $3.93, down 7.96% today, reflecting ongoing investor skepticism about its path to commercialization. The company remains pre-revenue with significant losses (-$435.05M net income in 2025) and negative profitability metrics (ROE -39.08%). Technical indicators show a bearish trend with oversold RSI readings, while analyst consensus leans heavily toward Hold (72.73%) with a $10.35 price target suggesting potential upside if execution improves.
QS faces substantial execution risk with commercialization delayed until at least 2029 and intense competition in solid-state batteries. The stock offers high-risk speculative potential for investors betting on breakthrough technology adoption, but requires patience through years of cash burn and dependency on future manufacturing success with partners like Volkswagen.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Kymera Therapeutics Inc. Common Stock
Kymera Therapeutics, Inc. is a biopharmaceutical company developing small-molecule medicines based on targeted protein degradation, using its Pegasus platform to direct the body's natural protein-disposal system against disease-causing proteins.
Read more on KYMR →About Quantumscape Corp
QuantumScape Corp is engaged in the development of next-generation solid-state lithium-metal batteries for use in electric vehicles. It developed anode-less cell design, which delivers high energy density while lowering material costs and simplifying manufacturing.
Read more on QS →
